Company Overview - Oddity Tech Ltd. (ODD) operates as a personal care company with a digital-first direct-to-consumer (DTC) model [1] - The company's brand portfolio includes Il Makiage, SpoiledChild, and the newer telehealth concept MethodIQ [1] Recent Challenges - ODD has encountered difficulties due to an abnormal spike in user acquisition costs, which are linked to recent changes in the market [1]

Core Insights - The Baron Small Cap Fund experienced a decline of 1.56% in Q4 2025, underperforming the Russell 2000 Growth Index, which gained 1.22% during the same period. For the entire year, the fund returned -0.66%, trailing the index by 13.67 percentage points, indicating weak performance both absolutely and relatively [1]. Group 1: Fund Performance - The Baron Small Cap Fund's performance in Q4 2025 was negative, with a decline of 1.56% compared to a gain of 1.22% for the Russell 2000 Growth Index [1]. - The fund's annual return for 2025 was -0.66%, significantly underperforming the index by 13.67 percentage points [1]. - Large-cap growth stocks continued to lead the market for the third consecutive year, suggesting a concentrated leadership trend [1]. Group 2: Oddity Tech Ltd. Analysis - Oddity Tech Ltd. (NASDAQ:ODD) was highlighted as a leading detractor for the Baron Small Cap Fund, with a one-month return of -14.31% and a 12-month decline of 28.64%, resulting in a market capitalization of approximately $1.73 billion [2]. - The company aims to transform the beauty and wellness market through proprietary technology for online sales, but faced stock declines due to investor concerns about category weakness and potential deceleration in its largest brand, Il Makiage [3]. - Oddity Tech Ltd. is launching a new platform, MethodIQ, which requires significant upfront marketing investment, adding uncertainty to its financial outlook [3]. Group 3: Hedge Fund Interest - Oddity Tech Ltd. was held by 31 hedge fund portfolios at the end of Q3 2025, a decrease from 36 in the previous quarter, indicating a decline in popularity among hedge funds [4]. - Despite its potential, the company is viewed as less favorable compared to certain AI stocks that are believed to offer greater upside potential and lower downside risk [4].

Company Overview - Oddity Tech, trading under NASDAQ:ODD, is recognized for its innovative beauty brands, Il Makiage and SpoiledChild, which have gained popularity due to their strong online presence and unique product offerings [1] - The company operates in the competitive beauty and skincare industry, facing competition from major players like Estée Lauder and L'Oréal [1] Financial Performance - Oddity's net revenue increased by 24% year over year, reaching $148 million, driven by strong online sales for its brands [3] - The company's gross margin improved to 71.6%, up from 69.9% the previous year, indicating effective cost management [3][6] - Adjusted net income soared by 26% to $25 million, or $0.40 per share, surpassing Wall Street's forecast of $0.35 per share [4][6] Market Activity - Following a price target set by Truist Financial at $80, indicating a potential increase of about 84.71%, ODD shares surged over 10% by midday [2][6] - The current stock price is $39.57, reflecting a 6.49% increase, with a market capitalization of approximately $2.25 billion [5]

Financial Data and Key Metrics Changes - The company reported a 24% year-over-year revenue growth, reaching $148 million in Q3 2025, exceeding guidance of 21% to 23% [16][19] - Adjusted diluted earnings per share increased to $0.40, surpassing guidance of $0.33 to $0.36 [18] - Gross margins expanded to 71.6%, up 170 basis points from the previous year, exceeding guidance of 68% [17] - Adjusted EBITDA for the quarter was $29 million, above the guidance of $26 million to $28 million [18] Business Line Data and Key Metrics Changes - Il Makiage experienced double-digit online revenue growth, with a target of $1 billion revenue by 2028 [11] - SpoiledChild is expected to generate $225 million in revenue for 2025, indicating strong performance [12] - International revenue increased approximately 40% year-over-year in the first nine months of 2025, with successful scaling in existing markets [11] Market Data and Key Metrics Changes - The company noted that 83% of revenue still comes from the U.S., with international markets contributing 17% [23] - New geographic expansions include Italy, Spain, Netherlands, Ireland, Sweden, and Denmark, with testing in Japan, Mexico, and Korea [24] Company Strategy and Development Direction - The launch of Methodic, a new brand focused on dermatology, aims to transform medical care with high-efficacy treatments [5][6] - The company plans to expand Methodic into new medical domains beyond dermatology in the future [7] - Continued investment in technology and innovation, particularly in AI and proprietary datasets, is a key focus for driving direct-to-consumer growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging industry backdrop, citing strong repeat customer rates as a buffer against acquisition cost increases [40] - The outlook for 2025 has been raised, with expected net revenue between $806 million and $809 million, representing 24% to 25% year-over-year growth [19] Other Important Information - The company ended the quarter with $793 million in cash and cash equivalents, plus an additional $200 million available on undrawn credit facilities [19] - Methodic's launch includes a significant media campaign, marking the largest TikTok activation in the company's history [10] Q&A Session Summary Question: Can you unpack the 40% year-to-date growth in international markets? - Management noted that 83% of revenue still comes from the U.S., with international growth being strategically important and focused on existing markets [23][24] Question: Thoughts on Methodic's ability to bring in new customers? - Management indicated that Methodic will attract both new and existing customers, with a mixed approach to user acquisition [25][27] Question: How to think about Methodic's brand for 2026? - Expectations are for Methodic to scale faster than SpoiledChild, with a focus on user acquisition and long-term growth [32][34] Question: Views on the health of the U.S. consumer? - Management acknowledged external softness but highlighted strong internal performance and repeat customer growth as mitigating factors [40] Question: Is the growth algorithm for 2026 any different? - No changes to the growth algorithm of 20% revenue growth and 20% adjusted EBITDA margin were indicated [42] Question: How replicable is the data model for international efforts? - Management confirmed a measured approach for Methodic, starting only in the U.S. before considering international expansion [64] Question: Are the molecules for Methodic prescription or non-prescription? - The initial products will be a combination of OTC and cosmetic, with a focus on non-prescription offerings [67][93] Question: What is the total addressable market (TAM) for Methodic? - The TAM is viewed in terms of the number of people suffering from chronic skin conditions, with a focus on improving access and outcomes [84]

Financial Data and Key Metrics Changes - ODDITY reported a 24% year-over-year revenue growth in Q3, reaching $148 million, exceeding guidance of 21% to 23% growth [16][19] - Adjusted diluted earnings per share increased to $0.40, surpassing guidance of $0.33 to $0.36 [18] - Gross margins expanded to 71.6%, up 170 basis points from the previous year, exceeding guidance of 68% [17] Business Line Data and Key Metrics Changes - Il Makiage experienced double-digit online revenue growth, with a target of $1 billion revenue by 2028 [11] - SpoiledChild is expected to generate $225 million in revenue for 2025, showing strong performance [12] - METHODIQ, the new brand, aims to launch 28 products addressing various skin conditions, with a focus on dermatology [8][9] Market Data and Key Metrics Changes - International revenue increased approximately 40% year-over-year in the first nine months of 2025, with significant growth in existing markets like the U.K. and Australia [11][24] - The U.S. still accounts for 83% of total revenue, indicating room for international expansion [23] Company Strategy and Development Direction - ODDITY is focused on expanding its international presence while responsibly managing growth across brands and geographies [23] - The company aims to leverage technology and innovation, particularly through ODDITY Labs, to enhance product offerings and consumer experience [14][52] - METHODIQ is positioned to transform the medical care system by providing high-efficacy treatments without traditional barriers [6][7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the industry but emphasized strong financial performance and growth potential [5][16] - The company raised its full-year guidance, expecting net revenue between $806 million and $809 million for 2025, representing 24% to 25% growth [19] - Management remains optimistic about the consumer environment, citing strong repeat purchase rates as a buffer against acquisition cost increases [40] Other Important Information - ODDITY plans to launch a major media campaign for METHODIQ, including a significant TikTok activation [10][89] - The company has a strong cash position with $793 million in cash and equivalents, plus $200 million available on undrawn credit facilities [19][60] Q&A Session Summary Question: Can you unpack the 40% year-to-date growth in international markets? - Management noted that 83% of revenue still comes from the U.S., with international growth primarily from existing markets like Canada and the U.K. [23][24] Question: How does METHODIQ plan to attract new customers? - METHODIQ is expected to draw customers from existing brands while also focusing on user acquisition [27] Question: What is the growth outlook for Il Makiage and SpoiledChild? - Management aims for sustained 20% growth across brands, with Il Makiage targeting $1 billion by 2028 [75] Question: How is the company addressing higher acquisition costs? - Management highlighted strong repeat purchase rates as a key factor in offsetting higher acquisition costs [40] Question: What is the financial profile of METHODIQ? - METHODIQ is expected to have a similar long-term growth framework as Il Makiage and SpoiledChild, with a focus on repeat business [50] Question: How will the company leverage its physician network for METHODIQ? - The company is currently using third-party networks for physicians and plans to integrate technology to enhance treatment outcomes [67]

Financial Data and Key Metrics Changes - Oddity reported a 24% year-over-year revenue growth, reaching $148 million in Q3 2025, exceeding guidance of 21% to 23% [13][14] - Adjusted diluted earnings per share increased to $0.40, surpassing guidance of $0.33 to $0.36 [16] - Gross margins expanded to 71.6%, up 170 basis points from the prior year, exceeding guidance of 68% [15] - Adjusted EBITDA for the quarter was $29 million, above the guidance of $26 million to $28 million [16] - The company ended the quarter with $793 million in cash and cash equivalents, plus an additional $200 million available on undrawn credit facilities [17] Business Line Data and Key Metrics Changes - Il Makiage experienced double-digit online revenue growth, on track to achieve $1 billion in revenue by 2028 [9] - SpoiledChild is expected to generate $225 million in revenue for 2025, indicating strong performance [10] - International revenue increased approximately 40% year-over-year in the first nine months of 2025, with significant growth in existing markets like the U.K. and Australia [9][10] Market Data and Key Metrics Changes - The company noted that 83% of revenue still comes from the U.S., with international markets contributing 17% [20] - New geographic expansions include Italy, Spain, Netherlands, Ireland, Sweden, and Denmark, with testing in Japan, Mexico, and Korea [21][22] Company Strategy and Development Direction - The launch of Methodic, a telehealth platform, aims to transform the medical care system, starting with dermatology [5][6] - Methodic is expected to feature 28 products addressing various skin conditions, with a focus on high-efficacy treatments [6][7] - The company plans to continue investing in its long-term growth engines, including Methodic and ODDITY Labs [16][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging industry backdrop, citing strong repeat customer rates as a buffer against acquisition cost increases [36] - The outlook for 2025 has been raised, with expected net revenue between $806 million and $809 million, representing 24% to 25% year-over-year growth [17] - Management remains bullish on Methodic's potential, emphasizing the unique market opportunity it presents [30][31] Other Important Information - The company is leveraging artificial intelligence and proprietary datasets to enhance its direct-to-consumer model [11] - Methodic's launch includes a significant media campaign, marking the largest TikTok activation in the company's history [8][9] Q&A Session Summary Question: Can you unpack the 40% year-to-date growth in international markets? - Management noted that while international growth is strong, 83% of revenue still comes from the U.S., and they plan to responsibly grow in international markets [20][21] Question: How is Methodic expected to drive new customer acquisition? - Management indicated that Methodic will attract both existing and new customers, with a mix of user acquisition strategies [25] Question: What are the expectations for SG&A in the context of the new brand launch? - Management stated that they are not ready to provide specific guidance for 2026 but expect Methodic to scale faster than SpoiledChild [29][32] Question: How does the company view the health of the U.S. consumer? - Management acknowledged softness in the consumer market but highlighted strong revenue and margin performance, driven by repeat customers [36] Question: What is the financial profile of Methodic? - Management expects Methodic to support long-term revenue growth and healthy unit economics, with lower gross margins initially due to prescription costs [44][45] Question: How will the company approach international expansion for Methodic? - Management confirmed that Methodic will initially focus on the U.S. market before considering international expansion [55]

Core Insights - Oddity Tech Ltd. is set to release its quarterly earnings on November 19, 2025, with an expected EPS of $0.35 and revenue of approximately $145.47 million [1][6] Company Developments - The launch of Methodiq, a telehealth platform for medical skincare, signifies Oddity's strategic entry into the medical-grade skincare market, competing with companies like Hims [2][6] - Methodiq offers 28 new products targeting skin conditions such as acne and eczema, with prices ranging from $29 to $59, making them accessible to a broad audience [2] - The development of Methodiq took four years and integrates investments in biotechnology and AI-based computational imaging, allowing for online diagnosis and personalized treatments [3] Financial Performance - Oddity has a price-to-earnings (P/E) ratio of 18.89, indicating the market's valuation of its earnings [4][6] - The price-to-sales ratio stands at 2.76, reflecting investor willingness to pay per dollar of sales [4] - The enterprise value to sales ratio is 1.92, showing the company's total valuation relative to its sales [4] - The company maintains a low debt-to-equity ratio of 0.065, indicating conservative debt use [5] - A current ratio of 6.32 suggests strong liquidity, ensuring the company can cover short-term liabilities [5] - An earnings yield of 5.29% demonstrates Oddity's ability to generate earnings from each dollar invested [5]

Group 1 - Oddity Tech Ltd. is recognized as one of the best performing new tech stocks, with a recent price target adjustment by KeyBanc from $90 to $80 while maintaining an Overweight rating [1][3] - The company reported a net revenue of $241 million in Q2 2025, reflecting a 25% year-over-year increase from $193 million in Q2 2024, with a gross profit of $174 million and a gross margin of 72.3% [2] - Oddity Tech has raised its full-year financial outlook for 2025, projecting net revenue between $799 million and $804 million, indicating a 23% to 24% annual growth, driven by strong online revenue growth and international expansion [3] Group 2 - Oddity Tech operates as a consumer tech company focused on building digital-first brands in the beauty and wellness sectors, both in the US and internationally [4]

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved a revenue growth of 26% to $509 million, generated adjusted EBITDA of $122 million, and free cash flow of $99 million, surpassing the entire free cash flow delivered in 2023 [5][25][32] - The adjusted EBITDA margin for Q2 was 28.8%, which compressed by approximately 350 basis points due to planned growth investments [31] - The gross margin expanded by 10 basis points year over year to 72.3%, exceeding guidance of 70.5% [30] Business Line Data and Key Metrics Changes - The company reported double-digit online growth in both its brands, Il Makiage and Spoiled Child, contributing to the overall revenue increase [26][10] - Il Makiage is on track to reach $1 billion in revenue by 2028, with international sales representing 15% of the business in 2024 [13][29] - Spoiled Child is projected to cross $200 million in revenue this year, having launched only three years ago [14] Market Data and Key Metrics Changes - International sales grew over 40% in the first half of 2025, amounting to approximately $85 million, with $75 million from established markets and $10 million from new testing markets [66] - The company is focusing on expanding its presence in international markets, which currently represent a smaller portion of its overall revenue compared to competitors [29][66] Company Strategy and Development Direction - The company aims to become one of the largest beauty companies globally, with a focus on expanding its online presence and entering the healthcare market [6][7] - Upcoming launches include Brand three, which will focus on medical-grade dermatology products, and Brand four next year [14][35] - Investments in technology and new brands are prioritized to sustain long-term growth and innovation [12][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% revenue growth and 20% adjusted EBITDA margin in the long term, even without contributions from new brands [34][44] - The company is preparing for a strong finish to 2025, driven by a backlog of repeat sales and a focus on long-term initiatives [11][34] Other Important Information - The company generated $99 million in free cash flow in the first half of 2025, converting over 80% of adjusted EBITDA into free cash [32] - The company has a remaining buyback authorization of $103 million with no share repurchases year to date [33] Q&A Session Summary Question: What is driving the sequential compression in gross margin for Q3? - Management explained that gross margin is not a primary metric they manage to, and seasonal factors contribute to lower margins in the second half of the year due to repeat business dynamics [40][42] Question: Will Brand three's success impact growth management for existing brands? - Management confirmed that they do not need Brand three for their 2025 or 2026 outlook, as existing brands have sufficient growth potential [44][45] Question: What is the strategy for Brand three's launch? - Management indicated that a soft launch will occur in Q3 to test the market, with a full launch planned for Q4 [52] Question: What are the growth drivers for international markets? - Management highlighted that international markets are expected to grow significantly, with a focus on deeper penetration and new market entries [63][66] Question: How does Brand three differ from previous launches? - Management noted that Brand three will leverage advanced technology and personalized treatment plans, setting it apart from traditional offerings [72][74]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue growth of 27% to $268 million, with adjusted EBITDA of $52 million, representing a 19.5% adjusted EBITDA margin and free cash flow of $87 million [4][22][23] - The company expects full-year revenue growth to be between 22% and 23%, or between $790 million and $798 million, raising its gross margin outlook to 71% for the full year [28][29] Business Line Data and Key Metrics Changes - The growth in net revenue was primarily driven by increased orders and a 4% year-over-year increase in average order value, influenced by a mix of higher-priced products [23][25] - The company continues to expect order growth to be the primary driver of revenue growth moving forward [24] Market Data and Key Metrics Changes - International markets contributed to growth, although they currently represent less than 20% of the business, with both U.S. and international markets growing in double digits in Q1 [34][60] - The company is focusing on scaling existing markets and testing new markets, with positive results from recent tests in large developing markets [61] Company Strategy and Development Direction - The company aims to build one of the largest beauty companies globally by focusing on online consumer shifts and high-efficacy products [5][6] - Strategic priorities include driving existing brands, accelerating international expansion, and investing in new brand launches and technology [9][10][18] Management's Comments on Operating Environment and Future Outlook - Management views the current environment as a significant opportunity, emphasizing the resilience of the beauty industry and the company's strong performance [20][21] - The company remains confident in its ability to exceed long-term growth targets of 20% revenue growth and 20% adjusted EBITDA margins despite potential tariff impacts [29] Other Important Information - The company has a strong balance sheet with $257 million in cash equivalents and investments, zero debt, and a new undrawn $200 million credit line [26][27] - The company is actively looking for acquisition opportunities that align with its strategic goals, particularly in technology and brands that complement its existing portfolio [62] Q&A Session Summary Question: Contribution of international markets to the quarter - Management confirmed that international markets are a core part of the growth strategy, with both U.S. and international markets growing double digits in Q1, although international is still less than 20% of the business [34][60] Question: Impact of the FTC's click-to-cancel rule - Management does not foresee significant impact from the regulation, as the company has already adapted its subscription and cancellation processes to be user-friendly and self-serve [36][37] Question: Factors driving gross margin increases - Management highlighted that gross margin improvements are due to cost efficiencies and product mix, with a focus on contribution margin rather than gross margin as a key performance indicator [42][45] Question: Updates on Brand three and telehealth infrastructure - Management expressed excitement about Brand three, emphasizing the extensive testing and infrastructure built to support its launch, which is expected to address significant consumer needs [51][73] Question: Strategic focus for acquisitions - Management indicated a focus on acquiring brands with strong products or capabilities that would take significant time to develop internally, particularly in biotech and AI [62]